Skip to main content

Sigma-Aldrich Posts 21-Percent Sales Growth in Q3 as Profit Surges 16 Percent

NEW YORK, Oct. 25 (GenomeWeb News) - Sigma-Aldrich today reported revenue of $412.2 million for the third quarter, a 21-percent increase over third-quarter 2004 sales of $340.6 million.


The firm said that the industrial cell culture business of JRH Biosciences, which it acquired in February 2005, contributed 11.3 percent of the total increase for the quarter. Organic growth accounted for 9 percent of the increase, Sigma said, while currency benefits contributed .7 percent of the increase.


Sigma said net income grew 16 percent in the period to $63.9 million, or $.94 per share, from $56.3 million, or $.81 per share, reported in the third quarter last year.


The firm's R&D spending increased to $12.8 million from $10.6 million year over year.


As of Sep. 30, Sigma-Aldrich had 155.3 million in cash balances.


Sigma said it predicts sales growth of 17 percent to 20 percent for the full year 2005.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.